Omar A. Kaoud

Omar A. Kaoud

Auto-generated profile, based on publicly available information

Omar A. Kaoud

Tanta University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
MMMostafa Hossam El Din Moawad
Mostafa Hossam El Din Moawad
MAMohammad Al-Jafari
Mohammad Al-Jafari
ATAmira Mohamed Taha
Amira Mohamed Taha
JAJenan Walid A’aMar
Jenan Walid A’aMar
OAOmar Alsayed
Omar Alsayed
ISIbrahim Serag
Ibrahim Serag
Background: There is evidence that individuals of African ancestry, particularly those residing in Africa, suffer from an unfortunate amount of under-representation in cancer research worldwide. Aim: We aimed to analyze current research output and potentially predict future trends in neuro-oncological research in Africa. Investigating deficits in the field will assist in identifying top-performing countries, which ones face challenges, and how to solve them. Therefore, targeted interventions can be applied to overcome these challenges. Methods: We conducted a systematic computer-based search on the following databases (PubMed, Scopus, Web of Science, and Embase) for research articles related to the neuro-oncological field in Africa. We aimed to retrieve any article published in the period between 1 January 2000 and 10 January 2023. Results: We included 200 eligible articles in our study. The output of neuro-oncological research has been increasing over the past two decades, peaking in 2019. Among the included articles, clinical practice issues constituted the majority (80%), while public health-related topics accounted for 20% of the publications. Regarding the type of neurological tumor, neuroblastoma was the most common, with 26 articles (13%), meningioma with 21 (10.5%), and glioma with 16 articles (8%). Conclusion: The interest in African neuro-oncological research is increasing. Hence, there is a need for ongoing efforts to address issues with clinical practice and public health related to neurological tumors in the continent. Future studies should concentrate on filling in knowledge gaps and investigating novel methods for neuro-oncological conditions that affect African populations in terms of prevention, diagnosis, treatment, and management strategies.

1 October 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
MMMostafa Hossam El Din Moawad
Mostafa Hossam El Din Moawad
SBSuhel Batarseh
Suhel Batarseh
AAAbdelaziz A. Awad
Abdelaziz A. Awad
RARaghad Amro
Raghad Amro
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
OBOsama Bisht
Osama Bisht
Background: The optimal timing for initiating oral anticoagulation (OAC) after acute ischemic stroke in patients with atrial fibrillation (AF) remains a critical clinical dilemma. Early anticoagulation may lower recurrent ischemic stroke risk but could raise hemorrhagic transformation risk, and current guidelines are conflicting. This meta-analysis examined the impact of early versus late initiation of anticoagulation on clinical outcomes—recurrent stroke, intracranial haemorrhage, Bleeding, mortality, transient ischemic attack (TIA), and thrombosis—in AF-related ischemic stroke. Methods: Following PRISMA guidelines, we conducted a systematic review and meta-analysis of observational and experimental studies that compared early and late anticoagulation; seventeen studies met inclusion criteria. Results: Early anticoagulation was associated with a significantly lower risk of recurrent ischemic stroke (OR = 0.72, 95% CI [0.55-0.96], P = .03). The incidence of intracranial hemorrhage did not differ significantly between groups (OR = 1.13, 95% CI [0.83-1.53], P = .44). No significant differences were observed for Bleeding (OR = 0.87, 95% CI [0.67-1.12], P = .27), mortality (OR = 0.94, 95% CI [0.72-1.24], P = .68), TIA (OR = 0.99, 95% CI [0.57-1.74], P = .98), or thrombosis (OR = 0.87, 95% CI [0.59-1.27], P = .47). Notable heterogeneity—likely due to differences in study design, anticoagulant type, and stroke severity—limits firm conclusions. Conclusion: Early anticoagulation appears to reduce ischemic recurrence without significantly increasing major hemorrhagic events, but randomized trials are needed to define optimal OAC timing.